Direkt zum Inhalt
Merck
  • Effects of the selective serotonin reuptake inhibitor, fluoxetine, on regional gastric contractility.

Effects of the selective serotonin reuptake inhibitor, fluoxetine, on regional gastric contractility.

Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society (2005-01-27)
A N James, J P Ryan, H P Parkman
ZUSAMMENFASSUNG

Selective serotonin reuptake inhibitors (SSRIs) are increasingly used to treat a variety of disorders but have gastrointestinal side-effects. To determine the effects of the SSRI, fluoxetine, on gastric smooth muscle contractility. Fundic, antral, and pyloric circular muscle contractility of guinea pig muscle strips were measured in vitro. Fluoxetine was added in concentrations from 0.1 nmol L(-1) to 100 mumol L(-1). Receptor antagonists were used to determine the neural pathways involved. Fluoxetine caused concentration dependent contractions, which were greatest in fundus compared with the antrum or pylorus. The contractile effects of fluoxetine in the antrum were reduced by tetrodotoxin, atropine, phentolamine, and the 5-HT(4) receptor antagonist GR 113808. The contractile effects of fluoxetine in the fundus were reduced by atropine, phentolamine, and GR 113808. Fluoxetine affects gastric contractility with regional variability - contracting the fundus more than the antrum or pylorus. The fluoxetine contractile effect is reduced by tetrodotoxin, atropine, phentolamine, and a 5-HT(4) receptor antagonist. These results suggest fluoxetine interacts with muscarinic, alpha-adrenergic, and serotoninergic receptors and/or ongoing reuptake/release of serotonin in the stomach.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
GR 113808, ≥98% (HPLC), solid